Use of antivirals and antibiotics for COVID-19 in Mexico City: A Real-World Multicenter Cohort Study

Javier Mancilla-Galindo[1,2] MBBS

Jorge Óscar García-Méndez[2,3,4] MD

Jessica Márquez-Sánchez[5] MD

Rodrigo Estefano Reyes-Casarrubias[2,3] MD

Eduardo Aguirre-Aguilar[6] MD

Héctor Isaac Rocha-González[7] PhD

Ashuin Kammar-García[6,7] PhD

[1].- Unidad de Investigación UNAM-INC, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.

[2].- Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico

[3].- Departamento de Posgrado y Educación Médica Continua, Instituto Nacional de Cancerología, Mexico City, Mexico.

[4].- Departamento de Infectología, Fundación Clínica Médica Sur, Mexico City, Mexico.

[5].- Departamento de Infectología, Instituto Nacional de Pediatría, Mexico City, Mexico.

[6].- Departamento de Atención Institucional Continua y Urgencias, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

[7].- Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City, Mexico.

*Corresponding author: A. Kammar-García. Vasco de Quiroga 15, Tlalpan, Col. Belisario Domínguez Sección XVI, CP 14080 Ciudad de México, México. Tel: +52 5554870900, ext. 5010, e-mail: kammar_nutrition@hotmail.com

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Abstract

We aimed to characterize real-world use of antivirals and antibiotics in patients with COVID-19 and their associations with mortality. We conducted a real-world retrospective cohort study in 688 primary-to-tertiary medical units in Mexico City; 395,343 patients were evaluated for suspected COVID-19 between February 24 and September 14, 2020. All patients with a positive RT-PCR for SARS-CoV-2 (n=137,012) were included; those receiving unspecified antivirals (n=137), excluded, and groups of antivirals with <30 patients (n=20), eliminated. Survival and mortality risk analyses were done for patients receiving antivirals, antibiotics, both, or none (exposition groups). 136,855 patients were analyzed; mean age 44.2 (SD:16.8) years; 51.3% were men. 16.6% received an antiviral (3%), antibiotic (10%), or both (3.6%). More symptomatic patients received antivirals and antibiotics more often. Antivirals studied were Oseltamivir (n=8414), Amantadine (n=319), Lopinavir-Ritonavir (n=100), Rimantadine (n=61), Zanamivir (n=39), and Acyclovir (n=36). Survival with antivirals (73.7%, P<.001) and antibiotics (85.8%, P<.001) was lower than no antiviral/antibiotic (93.6%) in the general population. Increased risk of death was observed with antivirals in ambulatory (HR=4.7, 95%CI:3.94-5.62) and non-critical (HR=2.03, 95%CI:1.86-2.21) patients; no benefit in hospitalized and critical patients. Oseltamivir was associated with increased mortality in the general population (HR=1.72, 95%CI:1.61-1.84), ambulatory (HR=4.79, 95%CI:4.01-5.75), non-critical (HR=2.05, 95%CI:1.88-2.23), and pregnancy (HR=8.35, 95%CI:1.77-39.30). Antibiotics were a protective factor in hospitalized (HR=0.81, 95%CI:0.77-0.86) and critical patients (HR=0.67, 95%CI:0.63-0.72), but a risk factor in the general population (HR=1.13, 95%CI:1.08-1.19) and children and adolescents

(HR=4.22, 95%CI:2.01-8.86). In conclusion, oseltamivir was associated with increased mortality or no benefit in all groups. Common antivirals for COVID-19 should be avoided. Antibiotics may increase survival in hospitalized and critical patients. Vaccination history and rapid differentiation of etiologic agent will be key to promptly initiate or avoid antivirals during the COVID-19-influenza season.

Introduction

The severe acute respiratory coronavirus 2 (SARS-CoV-2) is the etiologic agent of the coronavirus disease (COVID-19) pandemic, one of the most devastating infectious diseases of this century. Non-pharmacological interventions are the most effective means of limiting the impact of COVID-19 to date (1,2). However, several countries have not been able to contain the disease through such measures (3).

One of the main strategies for finding ways to combat COVID-19 has been drug repurposing since developing novel antivirals against SARS-CoV-2 may be protracted (4). Repurposing existing antivirals is an attractive approach due to their relative safeness and potential anti-SARS-CoV-2 mechanisms (5). Up to October 2, 2020 there were 369 registered studies to test antivirals for COVID-19, of which 360 were still active (6). The majority of trials in the World Health Organization (WHO) platform were for lopinavir/ritonavir (176), remdesivir (41), favipiravir (29), oseltamivir (18), and ribavirin (16) (7). Thus, comprehensive evidence for these antivirals may be available shortly. Other common antivirals are not being tested for COVID-19 but could be having widespread use in the community and hospitals since practice guidelines do not discourage or recommend most antivirals due to a lack of evidence (8,9), others advice against most (10-12), or recommend oseltamivir empirically during the influenza season (13) and when coinfection exists (14).

Real-world data studies may reveal valuable information not encountered in conventional interventional studies; while pragmatic clinical trials are designed to obtain answers for real-world problems, most other clinical trials are not, often having strict

selection criteria (15). Therefore, real-world studies have the potential to become into real-world evidence with immediate impact on policymaking (16,17).

In Mexico, epidemiologic surveillance of viral respiratory diseases started in 2006 and has expanded to include monitoring units representative of the Mexican population (18,19). Follow-up and reporting of cases, including monitorization of antivirals and antibiotics have been occurring since. This surveillance system was adapted to monitor COVID-19 and open datasets for Mexico (20) and Mexico City (21) were made available, the latter including use of antivirals and antibiotics.

In this study, we sought to characterize the use of antivirals and antibiotics in patients with laboratory-confirmed COVID-19 in Mexico City and their associations with mortality.

Methods

Study Design

We conducted a real-world multicenter retrospective cohort study in patients who received medical attention for suspected COVID-19 in any of the registered and accredited COVID-19 medical units in Mexico City, to evaluate mortality (main outcome) in those receiving antivirals, antibiotics, both, or none (exposition groups).

We considered 395,343 patients for eligibility who had been evaluated for COVID-19 in 688 medical units (primary-to-tertiary care) between February 24, 2020 and September 14, 2020. All patients with a positive RT-PCR for SARS-CoV-2 were included to maximize the power and generalizability of the study. Patients treated with an unspecified antiviral were excluded. To perform reliable analyses, a cut-off value of 30

patients receiving the same antiviral was set and groups of antivirals with <30 patients were eliminated.

Source of Data and Management of Variables

We used the COVID-19 open dataset available in Mexico City Government's Open Data platform (21), collected and updated daily by the Secretariat of Health of Mexico City. Patients meeting criteria of suspected COVID-19 case have been included in this dataset starting on February 24, 2020 when the first suspected cases arrived in Mexico. Criteria for suspected COVID-19 case in Mexico included having at least two of three signs/symptoms (cough, fever, or headache) plus at least one other (dyspnea, arthralgias, myalgias, sore throat, rhinorrhea, conjunctivitis, or chest pain) in the last 7 days. This operational definition was changed on August 24, 2020 to increase sensitivity (22): at least one of four signs/symptoms (cough, fever, dyspnea, or headache), plus at least one other (myalgias, arthralgias, sore throat, chills, chest pain, rhinorrhea, anosmia, dysgeusia, or conjunctivitis) in the last 10 days.

For epidemiologic purposes, two strategies are outlined in the National COVID-19 Epidemiologic Surveillance Plan (22): 1. testing of 10% of ambulatory patients with mild symptoms of respiratory disease and 100% of patients with respiratory distress at evaluation in monitoring units of viral respiratory disease (USMER, for its acronym in Spanish), and 2. testing 100% of patients who meet diagnostic criteria of Severe Acute Respiratory Infection (defined as shortness of breath, temperature ≥38 °C, cough, and ≥1 of the following: chest pain, tachypnea, or acute respiratory distress syndrome) in non-USMER units.

Upon evaluating a patient suspected of having COVID-19, healthcare professionals are required to fill out a format (Supplementary Appendix 1) containing demographic, clinical, epidemiological, and treatment variables, later complemented with follow-up by accredited hospital epidemiologists (inpatients) and healthcare professionals in primary care units (ambulatory patients). For ambulatory patients, follow-up is performed daily for a minimum 7 days and patients are considered recovered 14 days after the onset of symptoms if alive and not hospitalized. For hospitalized patients, follow-up is done daily until death or discharge; follow-up time for patients discharged from hospital is highly variable since no consensus or requirements by authorities exist but may extend from 14 days to 3-6 months after discharge. Duration of follow-up for each patient is not provided in the dataset and cannot be calculated.

For every medical unit there is only one responsible authority who ultimately uploads data into the Respiratory Diseases Epidemiologic Surveillance System and is accountable for accuracy. Results of diagnostic RT-PCR for SARS-CoV-2 are directly uploaded by the diagnostic facility; accreditation of diagnostic procedures by the Mexican Institute of Diagnostics and Epidemiological Reference is required to upload results. Reporting of all deaths of COVID-19 suspected or confirmed cases is obligatory and must be done in the first 48 hours after occurrence; in cases of deaths occurring in patients who had completed follow-up, registries are matched to death certificates and updated. There have been concerns that patients tested more than once may be duplicated. Since no variables that could lead to identification of patients are released, we searched for patients with identical demographic variables and only one registry was kept.

Management of Variables

All categorical variables were classified as dummy variables (present/absent). Polytomous variables were created from frequencies of use of antivirals and antibiotics (no antiviral/antibiotic, antiviral only, antibiotic only, and antiviral plus antibiotic), type of antiviral with >30 patients, and the combination of every individual antiviral with antibiotics. These were considered as the exposition groups. Special populations for subgroup analyses were defined as: children and adolescents (<18 years), pregnancy, puerperium, and non-pregnant/puerperal adults (≥18 years). Further subgroups included ambulatory and hospitalized patients, as well as patients admitted to intensive care unit (ICU) and those requiring invasive mechanical ventilation (IMV). A variable of critical patients was built by grouping patients admitted to ICU and/or requiring IMV, whereas non-critical patients did not meet any of both.

Since it has been hypothesized that early use of antivirals in COVID-19 could diminish hospitalization rate (23) and detain disease progression (24), thereby decreasing mortality, we distinguished early (≤2 days from symptom onset to initiation of antivirals) from late (>2 days) use of antivirals, and studied their relation to hospitalization rates and mortality; only patients with complete dates for all three variables (symptom onset, hospitalization [if required], and initiation of antivirals) were included for analysis. Occupations were grouped as follows: technical services (laborers), education (students and teachers), healthcare (dentists, nurses, diagnostic laboratorian, physicians, and other healthcare workers), agricultural activities (peasants), commerce (drivers, informal

commerce, employees, and businesspeople), unemployed, stay-at-home (stay-at-home parents and retired/pensioners), and other occupations (others, and other professions).

Statistical Analysis

Descriptive data were calculated and are provided as frequencies, percentages, mean with standard deviation (SD) or median with interquartile range (IQR). Qualitative comparisons were made with χ^2 or Fisher´s exact test. Independent-samples t-test and ANOVA were used for quantitative comparisons. Survival was calculated for all treatment groups (antiviral only, antibiotic only, antiviral plus antibiotic, and no antiviral/antibiotic) and specific antivirals (acyclovir, amantadine, lopinavir-ritonavir, oseltamivir, rimantadine, and zanamivir) alone or combined with antibiotics; survival curves were created for general population, ambulatory, hospitalized, non-critical, and critical patients. Survival between groups receiving distinct treatments were compared through the Log-Rank test against patients not receiving antivirals/antibiotics. Cox regression models were applied for general population, ambulatory, hospitalized, non-critical, and critical patients to determine mortality risk in patients receiving any treatment compared to no antivirals/antibiotics (reference). Resulting hazard ratios (HR) were adjusted for demographic and clinical variables (sex, age, indigenous self-identification, diabetes, chronic obstructive pulmonary disease [COPD], immunosuppression, hypertension, human immunodeficiency virus/acquired immune deficiency syndrome [HIV/AIDS], cardiovascular disease, obesity, chronic kidney disease [CKD], smokers, unemployed, time from symptom onset to medical attention, fever, cough, sore throat, shortness of breath, irritability, diarrhea, chest pain, chills, headache, myalgias, arthralgias, abrupt deterioration, rhinorrhea, polypnea, vomit,

abdominal pain, conjunctivitis, cyanosis, and sudden onset of symptoms) that were considered as risk factors in the univariate analysis for every group; all variables with P<.1 were included in the final model using the Enter method. To account for multicenter variability, adjusted risk was calculated through generalized estimating equations (GEE), setting the medical unit with the lowest CFR and the highest number of patients for every subgroup as the reference value. Further subgroup survival analyses and multivariable Cox regression models were applied for special populations (children and adolescents, pregnancy, puerperium, and non-pregnant/puerperal adults), VMI, and ICU. To quantify the minimal association strength of an unmeasured confounding factor that could reduce the risk conferred by exposures in our study, E-values were calculated for the point estimate and lower limit of the confidence interval.

A two-sided P value <.05 was used to define statistical significance. Analyses and figures were created with SPSS software v.21 and GraphPad Prism v.8.0.1.

Results

No duplicated registries were found. After selection of eligible participants (Figure 1), 136,855 patients from all 688 medical units were analyzed. 97.83% (n=133,887) were residents of the Mexico City Metropolitan Area, conformed by 17 municipalities of Mexico City (83.29%, n=111,768), and 60 municipalities (16.71%, n=22,119) of the State of Mexico. The remaining 2.17% (n=2,968) sought medical attention from all other 30 states of the republic.

Of all patients, 10.0% (n=13,743) received antibiotics only; 3.0% (n=4,044), antivirals only; 3.6% (n=4,925), antivirals plus antibiotics, and 83.4% (n=114,143), none (Table 1).

More symptomatic ambulatory patients received antivirals and antibiotics more frequently (Supplementary Table 1); hospitalized patients with more signs/symptoms had greater use of antivirals, but less antibiotics (Supplementary Table 2).

Baseline and follow-up characteristics of survivors (91.47%, n=136,855) and non-survivors (8.53%, n=11,679) are shown in Supplementary Table 3. Case-fatality rates (CFR) in special populations were: 8.92% (95%CI:8.76-9.07%), for non-pregnant/puerperal adults; 1.72% (95%CI:0.66-2.77), pregnancy; 0.97% (95%CI:0-2.90), puerperium; and 0.69% (95%CI:0.48-0.90), children and adolescents. Of all deaths, 92.7% (95%CI:92.2-93.2) and 99.6% (95%CI:99.5-99.7) occurred by day 28 and 56, respectively.

Patients treated only with antivirals had a lower survival than those not receiving antivirals or antibiotics in the general population (Figure 2a), ambulatory (Figure 2b), hospitalized (Figure 2c), non-critical (Figure 3a), critical (Figure 3c), IMV (Supplementary Table 4), ICU (Supplementary Table 5) and non-pregnant/puerperal adults (Supplementary Table 6); for children and adolescents (Supplementary Table 7) and pregnancy (Supplementary Table 8) differences in survival were not significant, and there were not enough events for analysis in puerperal women. Increased survival with only antibiotics was observed in hospitalized, critical, and IMV, whereas decreased survival occurred in the general population, non-pregnant/puerperal adults, ambulatory, non-critical, ICU, and children and adolescents; there were no differences for pregnancy. Antivirals plus antibiotics resulted in decreased survival in the general population, ambulatory, non-critical, non-pregnant/puerperal adults, children and

adolescents, pregnancy, and ICU; increased survival, in hospitalized; and no differences, in critical and IMV groups.

Decreased survival with oseltamivir was observed in the general population (Figure 2d), ambulatory (Figure 2e), non-critical (Figure 2d), ICU (Supplementary Table 5), non-pregnant/puerperal adults (Supplementary Table 6), children and adolescents (Supplementary Table 7), and pregnancy (Supplementary Table 8); no differences in survival occurred in hospitalized (Figure 2f), critical (Figure 3d), and IMV (Supplementary Table 4). Survival rates for amantadine, zanamivir, rimantadine, acyclovir, and lopinavir-ritonavir are shown in the same figures and tables as oseltamivir.

Unadjusted (Supplementary Table 9) and adjusted (Table 2) risk of death for the general population, ambulatory, hospitalized, non-critical and critical patients, as well as for other subgroups (Supplementary Tables 10-14) were calculated. E-values for statistically significant risk groups are provided in Supplementary Tables 15-16. After adjusting for center through GEE, we found no significant variability in risk for the use of antivirals, antibiotics, or both in all groups; oseltamivir presented variability in hospitalized and critical patients, with the largest increases in risk occurring in public hospitals.

Of all 8,969 patients receiving antivirals, 10% (n=903) had complete dates of initiation of antivirals; baseline and follow-up characteristics are available in Supplementary Table 17. 25.2% (n=227) were admitted to hospital. Most patients (n=783) initiated antivirals before receiving medical attention in accredited units; 211 of those were hospitalized. Median time from symptom onset to initiation of antivirals was 1 day (IQR:0-4) for both

ambulatory and hospitalized patients; time from symptom onset to ambulatory care in accredited units was 5 days (IQR:3-8) and 6 days (IQR:4-9) for hospitalization. Time from initiation of antivirals to hospitalization was 3 days (IQR:0-6). Time-to-initiation of antivirals and time-to-hospitalization for specific antivirals are shown in Supplementary Figure 1.

Early ($\leq$2 days) and late (>2 days) initiation of antivirals occurred in 64.2% (n=580) and 35.8% (n=323) patients, respectively. Overall survival in early (91.3%) and late (88.9%) groups was not different (P=.2). Survival for early/late use of antivirals is shown in Supplementary Table 18. Oseltamivir was associated with increased risk of death in both early (HR=3.00, 95%CI:2.14-4.20) and late (HR=2.99, 95%CI:1.83-4.89) groups, as well as late use of lopinavir-ritonavir (HR=9.9, 95%CI:2.49-39.83); all other early/late antivirals did not reach statistical significance. There were no differences in hospitalization rates between early and late groups for every antiviral (Supplementary Figure 2).

Discussion

To our best knowledge, this is the first observational study evaluating amantadine, rimantadine, zanamivir, and acyclovir for COVID-19; no registered studies to evaluate these drugs exist (7). Only one study has evaluated risk of death for oseltamivir (25); lopinavir-ritonavir has been evaluated in clinical trials (26,27).

We hypothesized that antivirals and antibiotics could be having widespread use in real-world settings. Therefore, we studied mortality in laboratory-confirmed COVID-19 patients treated with antivirals and/or antibiotics in Mexico City. Most patients were not

treated with antivirals or antibiotics (83.4%), although a substantial proportion received antivirals alone (3.0%) or combined with antibiotics (3.6%) despite national guidelines explicitly advising against antivirals out of clinical trials (12). Patients receiving antivirals and antibiotics were overall more symptomatic, suggesting that florid clinical presentations and not evidence may be guiding decision to treat, especially since evidence does not support antivirals included in our study: oseltamivir (n=8,414), amantadine (n=316), lopinavir-ritonavir (n=100), rimantadine (n=61), zanamivir (n=39), and acyclovir (n=31). Only one patient received remdesivir, the only antiviral to have shown some uncertain benefit for COVID-19 (28,29); physicians in low-to-middle income countries may be opting for low-cost repurposed medications before costly interventions for COVID-19.

Of patients treated with antivirals, 10% had dates of initiation of antivirals. These patients received antivirals early after symptom onset (1 day, IQR:0-4) and well before seeking ambulatory (5 days, IQR:3-8) or hospital (6 days, IQR:4-9) care, which was expected since date of initiation of antivirals is only required to be registered for those treated before seeking medical care in accredited units. In Mexico antibiotics and most antivirals (i.e. oseltamivir, zanamivir, rimantadine) are sold under prescription. Private pharmacy-associated clinics are a rapidly growing sector in Mexico not included in our study where physicians tend to have lower experience, qualifications, compliance with regulations, and higher prescription rates, which could partially explain this (30-32). Self-medication with amantadine could be occurring since it is a widely available over-the-counter antiviral combined with antihistamines and acetaminophen.

We studied the use of antivirals and antibiotics in patients with COVID-19 under conditions not commonly explored in COVID-19 studies since most tend to study hospitalized patients and adults, leaving important populations like children and adolescents, ambulatory patients, and pregnant women largely understudied (33,34). Our results show no benefit for the use of common antivirals for COVID-19 in the general population and every subgroup; increased risk of death was observed in certain groups. Hospitalization rates were not different when antivirals were used early (≤2 days) vs late (>2 days).

Oseltamivir was associated with increased mortality in the general population (HR=1.72, 95%CI:1.61-1.84), ambulatory (HR=4.79, 95%CI:4.01-5.75), non-critical (HR=2.05, 95%CI:1.88-2.23), and pregnant (HR=8.35, 95%CI:1.77-39.30) patients. Importantly, increased mortality was also observed in the cohort of 903 patients with both early (HR=3.00, 95%CI:2.14-4.20) and late (HR=2.99, 95%CI:1.83-4.89) use of oseltamivir. Antiviral drug-related heart damage is a concern since some antivirals may be cardiotoxic, aggravating myocardial damage caused by SARS-CoV-2 (35). It is unclear if cardiac adverse events after the use of neuraminidase inhibitors (i.e. oseltamivir, zanamivir) are increased or not due to high risk of bias of numerous influenza clinical trials; renal and psychiatric adverse events have higher occurrence with oseltamivir compared to placebo (36). Future studies should address if oseltamivir could be associated with cardiovascular and renal damage in COVID-19.

Through molecular docking studies, oseltamivir had been hypothesized to inhibit viral proteases involved in the degradation of polyproteins that control viral replication (37). Nonetheless, this potentially inhibitory activity was found to be weak through molecular

modeling, while inhibition of SARS-CoV-2 *in vitro* and reduction of symptoms in hospitalized patients failed (38). In one single-center study, oseltamivir was associated with decreased risk of death in COVID-19-hospitalized patients (HR=0.21; 95%CI:0.10-0.43) (25). Contrary to Liu et al., we found no benefit for oseltamivir in hospitalized patients (HR=1.07; 95%CI:0.99-1.15) which is consistent with studies of oseltamivir for SARS-CoV infection (HR=0.87; 95%CI:0.55-1.38) (39). Furthermore, combination of oseltamivir with antibiotics in hospitalized patients in our study resulted in decreased risk of death (HR=0.92; 95%:0.87-0.98), which could explain findings by Liu et al. since most patients in their cohort (87.7%) received antibiotics. Decreased mortality is most likely driven by antibiotics since hospitalized patients in our study receiving only antibiotics had lower risk of dying (HR=0.81, 95%CI:0.77-0.86) than antibiotics plus oseltamivir.

In the RECOVERY study, there were no differences in mortality risk between hospitalized patients receiving lopinavir-ritonavir vs placebo (HR=1.03, 95%CI:0.91-1.17) (27), which is consistent with our finding of no benefit for lopinavir-ritonavir in hospitalized patients. Notably, ambulatory and late (>2 days) use of lopinavir-ritonavir was a risk factor for death.

Paradoxically, antibiotics in the general population were a risk factor for death, but a protective factor in both ambulatory and hospitalized patients. Nonetheless, univariate models showed no overall effect of antibiotics in ambulatory patients; when adjusting only for demographic variables no effect persisted but was protective after adjusting only for clinical variables. This is explained by the fact that more symptomatic patients

received antibiotics more often. Supporting this conclusion, no benefit was observed for antibiotics in non-critical patients.

We observed benefit for antibiotics in hospitalized, IMV, and critical patients, suggesting that increased survival could be due to prevention or treatment of concomitant bacterial infections, thereby supporting current WHO recommendations (11).

For children and adolescents, antibiotics were a risk factor for death (HR=4.22, 95%CI:2.01-8.86). However, we did not differentiate ambulatory from hospitalized pediatric patients and current recommendations include using antibiotics in hospitalized patients with multisystem inflammatory syndrome (40). The lack of benefit from antivirals included in our study in pediatric patients supports current guidelines discouraging their use after the expected large number of patients treated needed to observe differences in mortality in both non-severe and severe COVID-19 which would not outweigh risks (41).

The main limitation of our study is that we were not able to assess cointerventions being studied for COVID-19 since only data for antivirals and antibiotics were available. Steroids have shown to increase survival in patients requiring oxygen administration and decrease survival in patients without supplementary oxygen (42,43). Under the assumption that treatment regimens tend to be similar by medical unit and hospital, we believe to have accounted for some of that variability by adjusting for center; lower risk for oseltamivir in hospitalized and critical patients receiving attention in private hospitals notwithstanding, increased risk of death with the use of oseltamivir occurred in most private and public hospitals. Furthermore, E-values aid the interpretation of our findings

by providing the estimated effect size that unmeasured factors in our study should have to reduce the reported risk to non-significant.

Categorization of antibiotics as a single category in this dataset limits our study since we were not able to evaluate individual antibiotics proposed as candidate drugs for COVID-19, like azithromycin. However, in vitro studies (44) and clinical trials (45,46) have failed to support an effect of azithromycin against SARS-CoV-2. Thus, generalized effects for the use of antibiotics is plausible.

Another potential limitation is that Mexico has a low diagnostic testing rate for SARS-CoV-2 (0.08 daily tests per 1,000 people) (47). However, health authorities require 100% of patients with severe disease to be tested. Since we only studied mortality, an outcome expected to occur in patients who progress to severe disease, our study feasibly included most events. Nonetheless, excess mortality rates suggest there could be an undercounting of deaths in Mexico City (47). These patients could have refrained from seeking medical attention or received medical care in non-accredited COVID-19 units where mortality, quality of care, and use of antivirals/antibiotics could be different.

Also, the number of ICU beds in Mexico City was relatively low in March 2020 (6.0 per 100,000 population) compared to most European countries (5 to 33.9 per 100,000) in the pre-pandemic period; this capacity was expanded to 29.5 ICU beds per 100,000 by September 2020 (48,49). Mortality rates, especially in patients younger than 60 years, are lower under high availability of ICU beds (48). Altogether, this means that mortality rates could have varied throughout our study period.

Although we were not able to determine duration of follow-up in our study, the mechanisms and resources used by epidemiologic authorities in Mexico are robust

enough to guarantee adequate matching of patients who had completed follow-up with death certificates. Thus, our finding that 92.7% (95%CI:92.2-93.2) and 99.6% (95%CI:99.5-99.7) of deaths occurred by day 28 and 56, respectively, could be important for the interpretation and design of COVID-19 clinical trials assessing short-term mortality.

In this study, we have obtained evidence to advise against the use of common antivirals (oseltamivir, zanamivir, amantadine, rimantadine, acyclovir, and lopinavir/ritonavir) for COVID-19 unless evidence from randomized controlled trials support their use in the future. Amantadine has been proposed as a candidate drug for COVID-19 (50), but our findings should discourage clinical trials to evaluate this drug.

During the COVID-19 and influenza syndemic, rapid differentiation of the etiologic agent will be of utmost importance since clinicians will have to differentiate patients with influenza who may benefit from neuraminidase inhibitors from patients with COVID-19 who may be harmed by them. Increasing vaccination rates against influenza will be a major challenge since only 20-30% of patients who presented with COVID-19 in our study had been vaccinated in the prior season. Mexican and international authorities should review treatment recommendations for patients with suspected viral respiratory disease since current guidelines recommend empiric use of oseltamivir before identification of the virus (13) or when coinfection exists (14).

Conclusions

Antivirals should be avoided for COVID-19 in the absence of evidence supporting their use. Oseltamivir was associated with increased mortality or no benefit in all groups.

Antibiotics may increase survival in hospitalized and critical patients. Amidst the upcoming combined COVID-19-influenza season, vaccination history and rapid differentiation of the etiologic agent will be key to initiate or avoid antivirals.

Ethical disclosures: This is a retrospective study using an open-source dataset of patients receiving medical care for suspected COVID-19 in Mexico City. The Secretariat of Health of Mexico approved the collection and publication of data.

Declarations of interest:

- Mancilla-Galindo: No competing interests.

- García-Mendez: No competing interests.

- Márquez-Sánchez: No competing interests.

- Aguilar-Aguirre: No competing interests.

- Reyes-Casarrubias: No competing interests.

- Rocha-González: No competing interests.

- Kammar-García: No competing interests.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Acknowledgements

We thank Dr. Sebastián Salinas Nájera, Head of Epidemiology in "Hospital Materno Infantil Magdalena Contreras" of Mexico City's Health Secretariat for his valuable clarifications of epidemiologic surveillance mechanisms in Mexico City. We also thank the Government of Mexico City for their effort to increase transparency and aid research by providing open datasets in their Open Data Platform; this sort of actions is most needed in low and middle-income countries to understand and solve the problems of our people. J Mancilla-Galindo would like to thank "Dirección General de Calidad y Educación en Salud" for supporting his participation in "Programa Nacional de Servicio Social en Investigación en Salud".

Author contributions

Kammar-García and Mancilla-Galindo had access to all data in the study and take responsibility for the integrity of the data and accuracy of analysis.

Concept and design: Kammar-García, Mancilla-Galindo

Acquisition, analysis, or interpretation of data: All authors

Drafting of the manuscript: All authors

Critical revision of the manuscript for important intellectual content: García-Méndez, Rocha-González, Kammar-García

Statistical analysis: Kammar-García, Mancilla-Galindo

Administrative, technical, or material support: Kammar-García

Supervision: Kammar-García, Mancilla-Galindo

References

1. Flaxman S, Mishra S, Gandy A, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature. 2020;584(7820):257-261. doi:10.1038/s41586-020-2405-7

2. Islam N, Sharp SJ, Chowell G, et al. Physical distancing interventions and incidence of coronavirus disease 2019: natural experiment in 149 countries. BMJ. 2020:m2743. doi:10.1136/bmj.m2743

3. Sachs JD, Abdool Karim S, Aknin L, et al. Lancet COVID-19 Commission Statement on the occasion of the 75th session of the UN General Assembly. Lancet. 2020;6736(20). doi:10.1016/S0140-6736(20)31927-9

4. Saul S, Einav S. Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19. ACS Infect Dis. 2020;6(9):2304-2318.doi:10.1021/acsinfecdis.0c00343

5. Senanayake SL. Drug repurposing strategies for COVID-19. Futur Drug Discov. 2020;2(2):6-8. doi:10.4155/fdd-2020-0010

6. National Institute for Health Research. COVID-19 Therapeutics. Innovation Observatory. http://www.io.nihr.ac.uk/report/covid-19-therapeutics/. Published 2020. Accessed October 7, 2020.

7. World Health Organization. International Clinical Trials Registry Platform (ICTRP). World Health Organization. https://www.who.int/ictrp/en/. Accessed October 7, 2020.

8. Cheng VC, Edwards KM, Gandhi R, Gallagher J. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-

19. IDSA Guidelines. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. Accessed October 2, 2020.

9. Panel C-19 TG. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/. Accessed October 2, 2020.

10. Jin Y-H, Zhan Q-Y, Peng Z-Y, et al. Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version). Mil Med Res. 2020;7(1):41. doi:10.1186/s40779-020-00270-8

11. World Health Organization. Clinical Management of COVID-19 - Interim Guidance. WHO. https://apps.who.int/iris/handle/10665/332196. Accessed October 2, 2020.

12. Mexican Secretariat of Health [Recommendations for treatment of SARS-CoV-2 infection, the etiologic agent of COVID-19] Spanish. Guidance documents for healthcare professionals. https://coronavirus.gob.mx/personal-de-salud/documentos-de-consulta/. Accessed October 2, 2020.

13. Mexican Secretariat of Health. [Diagnostic algorithm for acute respiratory disease in the context of the COVID19-influenza syndemic]. Guidance documents for healthcare professionals. https://coronavirus.gob.mx/personal-de-salud/documentos-de-consulta/. Accessed October 5, 2020.

14. Falavigna M, Colpani V, Stein C, et al. Guidelines for the pharmacological treatment of COVID-19. The task force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious

Diseases and the Brazilian Society of Pulmonology and Tisiology. Rev Bras Ter Intensiva. 2020;32(2):166-196. doi:10.5935/0103-507X.20200039

15. Haff N, Choudhry NK. The Promise and Pitfalls of Pragmatic Clinical Trials for Improving Health Care Quality. JAMA Netw Open. 2018;1(6):e183376. doi:10.1001/jamanetworkopen.2018.3376

16. Bolislis WR, Fay M, Kühler TC. Use of Real-world Data for New Drug Applications and Line Extensions. Clin Ther. 2020;42(5):926-938. doi:10.1016/j.clinthera.2020.03.006

17. Sun X, Tan J, Tang L, Guo JJ, Li X. Real world evidence: experience and lessons from China. BMJ. 2018;360:j5262. doi:10.1136/bmj.j5262

18. Ruiz-Matus C, Kuri-Morales P, Narro-Robles J. [Behavior of influenza seasons in Mexico from 2010 to 2016: Analysis and prospective]. Gac Med Mex. 2017;153(2):205-213.

19. Kuri-Morales PA, Díaz del Castillo-Flores G, Castañeda-Prado A, Pacheco-Montes SR. Clinical-epidemiological profile of deaths from influenza with a history of timely vaccination, Mexico 2010-2018. Gac Med Mex. 2020;155(5):423-429. doi:10.24875/GMM.M20000327

20. Mexican Secretariat of Health. Information regarding COVID-19 cases in Mexico [Spanish]. Datos Abiertos. https://datos.gob.mx/busca/dataset/informacion-referente-a-casos-covid-19-en-mexico. Accessed September 14, 2020.

21. Government of Mexico City. Covid-19 National Epidemiologic Surveilance System (SINAVE) Mexico City [Spanish]. Open Data Platform.

https://datos.cdmx.gob.mx/explore/dataset/base-covid-sinave/information/.
Accessed September 14, 2020.

22. Directorate General of Epidemiology of Mexico. Standardized Guideline for Epidemiologic and Laboratory Surveillance of viral respiratory diseases, Aug 2020 [Spanish]. Mexican Secretariat of Health. https://www.gob.mx/salud/documentos/lineamiento-estandarizado-para-la-vigilancia-epidemiologica-y-por-laboratorio-de-la-enfermedad-respiratoria-viral. Accessed September 17, 2020.

23. Benlloch JM, Cortés JC, Martínez-Rodríguez D, Julián R-S, Villanueva R-J. Effect of the early use of antivirals on the COVID-19 pandemic. A computational network modeling approach. Chaos, Solitons & Fractals. 2020;140:110168. doi:10.1016/j.chaos.2020.110168

24. Lipsitch M, Perlman S, Waldor MK. Testing COVID-19 therapies to prevent progression of mild disease. Lancet Infect Dis. 2020;3099(20):30372. doi:10.1016/S1473-3099(20)30372-8

25. Liu J, Zhang S, Wu Z, et al. Clinical outcomes of COVID-19 in Wuhan, China: a large cohort study. Ann Intensive Care. 2020;10(1):99. doi:10.1186/s13613-020-00706-3

26. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382(19):1787-1799. doi:10.1056/NEJMoa2001282

27. Horby PW, Mafham M, Bell JL, et al. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;19(20):1-8. doi:10.1016/S0140-6736(20)32013-4

28. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — Final Report. [published online October 8, 2020]. N Engl J Med. doi: 10.1056/NEJMoa2007764.

29. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19. JAMA. 2020;324(11):1048. doi:10.1001/jama.2020.16349

30. López-Manning M, García-Díaz R. Doctors Adjacent to Private Pharmacies: The New Ambulatory Care Provider for Mexican Health Care Seekers. Value Heal Reg Issues. 2017;14:81-88. doi:10.1016/j.vhri.2017.08.010

31. Pérez-Cuevas R, Doubova S V., Wirtz VJ, Servan-Mori E, Dreser A, Hernández-Ávila M. Effects of the expansion of doctors' offices adjacent to private pharmacies in Mexico: secondary data analysis of a national survey. BMJ Open. 2014;4(5):e004669. doi:10.1136/bmjopen-2013-004669

32. Wirtz VJ, Díaz-Portillo SP, Idrovo álvaro J, Dreser A, Bonilla FR, Matías-Juan B. Clinics adjacent to private pharmacies in Mexico: infrastructure and characteristics of the physicians and their remuneration. Salud Pública de Mex. 2015;57(4):320. doi:10.21149/spm.v57i4.7575

33. Whitehead CL, Walker SP. Consider pregnancy in COVID-19 therapeutic drug and vaccine trials. Lancet. 2020;395(10237):e92. doi:10.1016/S0140-6736(20)31029-1

34. Park JJH, Decloedt EH, Rayner CR, Cotton M, Mills EJ. Clinical trials of disease stages in COVID 19: complicated and often misinterpreted. Lancet Glob Heal. 2020;8(10):e1249-e1250. doi:10.1016/S2214-109X(20)30365-X

35. Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020;38(7):1504-1507. doi:10.1016/j.ajem.2020.04.048

36. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev. 2014(4):CD008965. doi:10.1002/14651858.CD008965.pub4

37. Muralidharan N, Sakthivel R, Velmurugan D, Gromiha MM. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19. [published online April 16, 2020]. J Biomol Struct Dyn. doi:10.1080/07391102.2020.1752802

38. Tan Q, Duan L, Ma YL, et al. Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study. [published online September 2, 2020]. Bioorg Chem. doi:10.1016/j.bioorg.2020.104257

39. Shi Q, Zhou Q, Wang X, et al. Potential effectiveness and safety of antiviral agents in children with coronavirus disease 2019: a rapid review and meta-analysis. Ann Transl Med. 2020;8(10):624-624. doi:10.21037/atm-20-3301

40. Harwood R, Allin B, Jones CE, et al. A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. [published online

September 18, 2020]. Lancet Child Adolesc Heal. doi:10.1016/s2352-4642(20)30304-7

41. Ye Z, Rochwerg B, Wang Y, et al. Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline. Can Med Assoc J. 2020;192(20):E536-E545. doi:10.1503/cmaj.200648

42. Sterne JAC, Murthy S, Diaz J V., et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19. JAMA. 2020;324(13):1330. doi:10.1001/jama.2020.17023

43. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. N Engl J Med. July 2020:NEJMoa2021436. doi:10.1056/NEJMoa2021436

44. Maisonnasse P, Guedj J, Contreras V, et al. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Nature. 2020;585(7826):584-587. doi:10.1038/s41586-020-2558-4

45. Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. [published online July 23, 2020]. N Engl J Med. doi:10.1056/NEJMoa2019014

46. Furtado RHM, Berwanger O, Fonseca HA, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020;396(10256):959-967. doi:10.1016/S0140-6736(20)31862-6

47. Roser M, Ritchie H, Ortiz-Ospina E, Hasell J. Coronavirus Pandemic (COVID-19). OurWorldInData.org. https://ourworldindata.org/coronavirus. Accessed October 2, 2020.

48. Karagiannidis C, Mostert C, Hentschker C, et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med. 2020;2600(20):1-10. doi:10.1016/S2213-2600(20)30316-7

49. Government of Mexico City. Report of the intervention of Mexico City's Government amidst COVID-19. Second Government Report. https://covid19.cdmx.gob.mx/storage/app/media/Informe de gobierno/Visual Estrategia COVID-19 - Informe de Gobierno 14.09.2020.pdf. Accessed October 2, 2020.

50. Aranda-Abreu GE, Hernández-Aguilar ME, Herrera-Covarrubias D, Rojas-Durán F. Amantadine as a drug to mitigate the effects of COVID-19. [published online April 25, 2020]. Med Hypotheses. doi:10.1016/j.mehy.2020.109755

Table 1. Baseline characteristics of patients with laboratory confirmed COVID-19 who were treated with or without antivirals/antibiotics, in 688 accredited COVID-19 medical units in Mexico City.

	All patients n=136855	No antiviral / antibiotic n=114143	Antiviral only n=4044	Acyclovir n=36	Amantadine n=319	Lopinavir-Ritonavir n=100	Oseltamivir n=8414	Rimantadine n=61	Zanamivir n=39	Antibiotic only n=13743
Sex										
Women	66683 (48.7)	56999 (49.9)	1813 (44.8)	19 (52.8)	182 (57.1)	31 (31)	3407 (40.5)	28 (45.9)	17 (43.6)	6000 (43.7)
Men	70172 (51.3)	57144 (50.1)	2231 (55.2)	17 (47.2)	137 (42.9)	69 (69)	5007 (59.5)	33 (54.1)	22 (56.4)	7743 (56.3)
Age, mean (SD)	44.2 (16.8)	43.1 (16.6)	50.5 (16.5)	46.9 (14.9)	43.9 (14.8)	56.9 (15.9)	51.8 (15.9)	46 (15.1)	50 (14.1)	48.3 (16.8)
Age categories										
0-19 years	7558 (5.5)	6963 (6.1)	57 (1.4)	0 (0)	12 (3.8)	1 (1)	97 (1.2)	2 (3.3)	0 (0)	483 (3.5)
20-29 years	20098 (14.7)	18027 (15.8)	375 (9.3)	6 (16.7)	38 (11.9)	2 (2)	638 (7.6)	5 (8.2)	3 (7.7)	1379 (10)
30-39 years	29434 (21.5)	25586 (22.4)	707 (17.5)	6 (16.7)	86 (27.0)	10 (10)	1286 (15.3)	16 (26.2)	7 (17.9)	2437 (17.7)
40-49 years	29553 (21.6)	24683 (21.6)	837 (20.7)	10 (27.8)	71 (22.3)	21 (21)	1780 (21.2)	14 (23)	8 (20.5)	2966 (21.6)
50-59 years	24928 (18.2)	20011 (17.5)	852 (21.1)	5 (13.9)	63 (19.7)	23 (23)	1895 (22.5)	15 (24.6)	10 (25.6)	2906 (21.1)
60-69 years	15070 (11.0)	11441 (10.0)	632 (15.6)	7 (19.4)	32 (10)	18 (18)	1515 (18.0)	3 (4.9)	6 (15.4)	2048 (14.9)
70-79 years	7183 (5.2)	5213 (4.6)	418 (10.3)	2 (5.6)	14 (4.4)	17 (17)	855 (10.2)	5 (8.2)	5 (12.8)	1072 (7.8)
80-89 years	2594 (1.9)	1902 (1.7)	146 (3.6)	0 (0)	2 (0.6)	8 (8)	292 (3.5)	1 (1.6)	0 (0)	389 (2.8)
90-99 years	419 (0.3)	303 (0.3)	20 (0.5)	0 (0)	1 (0.3)	0 (0)	56 (0.7)	0 (0)	0 (0)	59 (0.4)
≥100 years	18 (0.01)	14 (0.01)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (0.03)
Indigenous self-identification	713 (0.5)	537 (0.5)	37 (0.9)	0 (0)	2 (0.6)	1 (1)	79 (0.9)	0 (0)	2 (5.1)	92 (0.7)
Occupation										
Technical services	1916 (1.4)	1527 (1.3)	70 (1.7)	0 (0)	3 (0.9)	3 (3)	145 (1.7)	0 (0)	1 (2.6)	237 (1.7)
Education	10006 (7.3)	9129 (8)	105 (2.6)	1 (2.8)	24 (7.5)	1 (1)	187 (2.2)	2 (3.3)	0 (0)	662 (4.8)
Healthcare	17281 (12.6)	14910 (13.1)	655 (16.2)	3 (8.3)	47 (14.7)	9 (9)	1029 (12.2)	7 (11.5)	2 (5.1)	1274 (9.3)
Agricultural activities	302 (0.2)	232 (0.2)	5 (0.1)	0 (0)	0 (0)	0 (0)	19 (0.2)	0 (0)	0 (0)	51 (0.4)
Commerce	50450 (36.9)	42625 (37.3)	1078 (26.7)	15 (41.7)	111 (34.8)	36 (36)	2569 (30.5)	27 (44.3)	12 (30.8)	5055 (36.8)
Other	24630 (18)	19906 (17.4)	911 (22.5)	6 (16.7)	63 (19.7)	20 (20)	2021 (24)	9 (14.8)	6 (15.4)	2599 (18.9)
Unemployed	5685 (4.2)	4747 (4.2)	277 (6.8)	1 (2.8)	5(1.6)	2 (2)	463 (5.5)	3 (4.9)	7 (17.9)	457 (3.3)
Stay-at-home	26585 (19.4)	21067 (18.5)	943 (23.3)	10 (27.8)	66 (20.7)	29 (29)	1981 (23.5)	13 (21.3)	11 (28.2)	3408 (24.8)
Last-season flu vaccination	27087 (19.8)	22972 (20.1)	695 (17.2)	9 (25)	85 (26.6)	9 (9)	1244 (14.8)	13 (21.3)	4 (10.3)	2751 (20)
Special populations										
Pregnancy	583 (0.9)	530 (0.9)	12 (0.3)	0 (0)	2 (1.1)	0 (0)	16 (0.5)	0 (0)	0 (0)	35 (0.6)
Age during pregnancy, mean (SD)	29.8 (7.4)	29.5 (6.9)	30.3 (5.2)	-	32 (4.2)	-	30 (5.9)	-	-	34.8 (12.4)
Last-season flu vaccination	161 (27.6)	153 (28.9)	1 (8.3)	0 (0)	0 (0)	0 (0)	1 (6.3)	0 (0)	0 (0)	7 (20)
Pregnancy age group										
Early adolescent (≤14 years)	2 (0.3)	2 (0.4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Late adolescent (15-19 years)	34 (5.8)	33 (6.2)	1 (8.3)	0 (0)	0 (0)	0 (0)	1 (6.3)	0 (0)	0 (0)	0 (0)
Normal age (20-34 years)	404 (69.3)	373 (70. 4)	9 (75)	0 (0)	1 (50)	0 (0)	12 (75)	0 (0)	0 (0)	18 (51.4)
Advanced maternal age (≥35 years)	143 (24.5)	122 (23)	2 (16.7)	0 (0)	1 (50)	0 (0)	3 (18.8)	0 (0)	0 (0)	17 (48.6)
Trimester of pregnancy										
First trimester	114 (19.6)	102 (19.2)	5 (41.7)	0 (0)	1 (50)	0 (0)	5 (31.3)	0 (0)	0 (0)	6 (17.1)
Second trimester	177 (30.4)	161 (30.4)	3 (25)	0 (0)	0 (0)	0 (0)	4 (25)	0 (0)	0 (0)	12 (34.3)
Third trimester	292 (50.1)	267 (50.4)	4 (33.3)	0 (0)	1 (50)	0 (0)	7 (43.8)	0 (0)	0 (0)	17 (48.6)
Puerperium	103 (0.2)	64 (0.1)	2 (0.05)	0 (0)	0 (0.0)	0 (0)	7 (0.2)	0 (0)	0 (0)	32 (0.5)
Days of puerperium										
1 day	33 (32)	21 (32.8)	1 (50)	0 (0)	0 (0)	0 (0)	3 (42.9)	0 (0)	0 (0)	9 (28.1)
2-7 days	33 (32)	16 (25)	1 (50)	0 (0)	0 (0)	0 (0)	3 (42.9)	0 (0)	0 (0)	14 (43.8)

8-42 days	37 (35.9)	27 (42.2)	0 (0)	0 (0)	0 (0)	0 (0)	1 (14.3)	0 (0)	0 (0)	9 (28.1)
Age during puerperium, mean (SD)	31.9 (9.7)	31.1 (9.2)	33.5 (3.5)	-	-	-	31.1 (2.7)	-	-	33.6 (11.5)
Last-season flu vaccination	22 (21.4)	14 (21.9)	14 (21.9)	0 (0)	0 (0)	0 (0)	1 (14.3)	0 (0)	0 (0)	7 (21.9)
Children and adolescents (<18 years)	5791 (4.2)	5336 (4.7)	40 (1)	0 (0)	9 (2.8)	1 (1)	67 (0.8)	2 (3.3)	0 (0)	376 (2.7)
Age, mean (SD)	10.9 (5.2)	10.9 (5.2)	10.9 (5.9)	-	13.4 (4.5)	-	11 (5.8)	14.5 (3.6)	-	9.9 (5.9)
Last-season flu vaccination	1213 (20.9)	1113 (20.9)	4 (10)	0 (0)	1 (11.1)	0 (0)	9 (13.4)	0 (0)	0 (0)	90 (23.9)
Non-pregnant/puerperal adults (≥18 years)	130378 (95.3)	108213 (94.8)	3990 (98.7)	36 (100)	308 (96.6)	99 (9)	8324 (98.9)	59 (96.7)	39 (100)	13300 (96.8)
Age, mean (SD)	45.7 (15.5)	44.7 (15.3)	50.9 (16.1)	46.9 (14.9)	44.8 (14)	57.5 (15.1)	52.1 (15.6)	47.1 (14.1)	50 (14.1)	48.5 (15.7)
Last-season flu vaccination	25691 (19.7)	21692 (20)	690 (17.3)	9 (25)	84 (27.3)	9 (9.1)	1233 (14.8)	13 (22)	4 (10.3)	2647 (19.9)
Comorbidities										
Diabetes	18229 (13.3)	13458 (11.8)	910 (22.5)	2 (5.6)	36 (11.3)	35 (35)	2007 (23.9)	8 (13.1)	6 (15.4)	2677 (19.5)
COPD	1741 (1.3)	1273 (1.1)	119 (2.9)	0 (0)	3 (0.9)	2 (2)	212 (2.5)	2(3.3)	1 (2.6)	248 (1.8)
Asthma	3035 (2.2)	2561 (2.2)	96 (2.4)	1 (2.8)	13 (4.1)	4 (4)	165 (2)	0 (0)	3 (7.7)	288 (2.1)
Immunosuppression	1758 (1.3)	1368 (1.2)	84 (2.1)	0 (0)	7 (2.2)	3 (3)	145 (1.7)	0 (0)	0 (0)	235 (1.7)
Hypertension	22185 (16.2)	16799 (14.7)	1074 (26.6)	10 (27.8)	40 (12.5)	35 (35)	2211 (26.3)	12 (19.7)	5 (12.8)	3073 (22.4)
HIV/AIDS	573 (0.4)	462 (0.4)	168 (4.2)	0 (0)	0 (0)	2 (2)	47 (0.6)	0 (0)	0 (0)	62 (0.5)
Cardiovascular disease	2724 (2.0)	2064 (1.8)	153 (3.8)	2 (5.6)	4 (1.3)	5 (5)	277 (3.3)	2 (3.3)	0(0)	370 (2.7)
Obesity	23848 (17.4)	18924 (16.6)	837 (20.7)	12 (33.3)	83 (26)	18 (18)	1817 (21.6)	5 (8.2)	6 (15.4)	2983 (21.7)
Chronic kidney disease	2067(1.5)	1471 (1.3)	150 (3.7)	0 (0)	2 (0.6)	7 (7)	286 (3.4)	1 (1.6)	0 (0)	300 (2.2)
Smoker	14727 (10.8)	12214 (10.7)	461 (11.4)	2 (5.6)	46 (14.4)	6 (6)	885 (10.5)	8 (13.1)	5 (12.8)	1561 (11.4)
Type of medical attention										
Ambulatory	109902 (80.3)	98060 (85.9)	2012 (49.8)	30 (83.3)	282 (88.4)	8 (8)	3187 (37.9)	48 (78.7)	19 (48.7)	8268 (60.2)
Hospitalization	26953 (19.7)	16083 (14.1)	2032 (50.2)	6 (16.7)	37 (11.6)	92 (92)	5227 (62.1)	13 (21.3)	20 (51.3)	5475 (39.8)
Severity of the disease										
Non-critical	129658 (94.7)	110009 (96.4)	3518 (87)	34 (94.4)	310 (97.2)	69 (69)	7126 (84.7)	58 (95.1)	34 (87.2)	12018 (87.4)
Critical	7197 (5.3)	4134 (3.6)	526 (13)	2 (5.6)	9 (2.8)	31 (31)	1288 (15.3)	3 (4.9)	5 (12.8)	1725 (12.6)
Time from symptom onset to medical attention	4.5 (3.8)	4.4 (3.8)	4.49 (3.9)	6.36 (4.6)	4.9 (3.6)	6.8 (4.1)	4.7 (3.7)	5.6 (4.2)	5.33 (4.7)	5.5 (3.8)
Baseline symptoms										
Fever	83120 (60.7)	66011 (57.8)	3332 (82.4)	25 (69.4)	198 (62.1)	81 (81)	6963 (82.8)	42 (68.9)	31 (79.5)	9769 (71.1)
Cough	96206 (70.3)	78367 (68.7)	3406 (84.2)	24 (66.7)	245 (76.8)	67 (67)	7055 (83.8)	42 (68.9)	35 (89.7)	10371 (75.5)
Sore throat	59040 (43.1)	48845 (42.8)	2014 (49.8)	12 (33.3)	159 (49.8)	31 (31)	3701 (44)	29 (47.5)	22 (56.4)	6241 (45.4)
Shortness of breath	42942 (31.4)	31061 (27.2)	2234 (55.2)	14 (38.9)	85 (26.6)	66 (66)	5170 (61.4)	22 (36.1)	23 (59)	6501 (47.3)
Irritability	24098 (17.6)	19460 (17)	1079 (26.7)	5 (13.9)	81(25.4)	7 (7)	1993 (23.7)	14 (23)	13 (33.3)	2525 (18.4)
Diarrhea	31649 (23.1)	25821 (22.6)	1152 (28.5)	11 (30.6)	96 (30.1)	19 (19)	2180 (25.9)	15 (24.6)	13 (33.3)	3494 (25.4)
Chest pain	36851 (26.9)	29524 (25.9)	1662 (41.1)	12 (33.3)	105 (32.9)	22 (22)	2979 (35.4)	25 (41)	15 (38.5)	4169 (30.3)
Chills	48282 (35.3)	39405 (34.5)	2138 (52.9)	16 (44.4)	158 (49.5)	34 (34)	3616 (43)	33 (54.1)	17 (43.6)	5003 (36.4)
Headache	95018 (69.4)	78893 (69.1)	3284 (81.2)	22 (61.1)	227 (71.2)	59 (59)	6348 (75.4)	40 (65.6)	29 (74.4)	9400 (68.4)
Myalgias	70666 (51.6)	57192 (50.1)	2633 (65.1)	27 (75)	201 (63.0)	60 (60)	5074 (60.3)	43 (70.5)	24 (61.5)	8045 (58.5)
Arthralgias	64381 (47)	51792 (45.4)	2377 (58.8)	22 (61.1)	179 (56.1)	48 (48)	4846 (57.6)	42(68.9)	23 (59)	7429 (54.1)
Abrupt deterioration	62460 (45.6)	48991 (42.9)	2704 (66.9)	20 (55.6)	180 (56.4	66 (66)	5367 (63.8)	34 (55.7)	20 (51.3)	7782 (56.6)
Rhinorrhea	38288 (28)	32135 (28.2)	1350 (33.4)	6 (16.7)	118 (37.0)	20 (20)	2283 (27.1)	27 (44.3)	11 (28.2)	3688 (26.8)
Polypnea	15868 (11.6)	11977 (10.5)	1081 (26.7)	3 (8.3)	46 (14.4)	13 (13)	1847 (22)	7 (11.5)	6 (15.4)	1969 (14.3)
Vomit	10123 (7.4)	8094 (7.1)	479 (11.8)	3 (8.3)	23 (7.2)	7 (79	870 (10.3)	8 (13.1)	2 (5.1)	1116 (8.1)
Abdominal pain	17338 (12.7)	14080 (12.3)	1025 (25.3)	3 (8.3)	60 (18.8)	8 (8)	1561 (18.6)	10 (16.4)	7 (17.9)	1609 (11.7)
Conjunctivitis	16941 (12.4)	14277 (12.5)	513 (12.7)	4 (11.1)	55 (17.2)	7 (7)	962 (11.4)	11 (18)	6 (15.4)	1619 (11.8)
Cyanosis	5917 (4.3)	4461 (3.9)	463 (11.4)	1 (2.8)	12 (3.8)	4 (4)	816 (9.7)	8 (13.1)	3 (7.7)	612 (4.5)
Sudden onset of symptoms	46723 (34.1)	37607 (32.9)	1574 (38.9)	10 (27.8)	96 (30.1)	48 (48)	3831 (45.5)	26 (42.6)	16 (41)	5089 (37)
Concomitant use of antibiotics	18840 (13.8)	172 (0.2)	-	29 (80.6)	151 (47.3)	77 (77)	4627 (55)	26 (42.6)	15 (38.5)	-

Data expressed as Frequency (%) or mean (SD)

SD: Standard deviation, COPD: Chronic obstructive pulmonary disease, HIV/AIDS: Human immunodeficiency virus/acquired immune deficiency syndrome.

Table 2. Adjusted multivariable Cox regression models for mortality risk in laboratory-confirmed COVID-19 patients receiving antivirals, antibiotics, both, or none in 688 accredited COVID-19 medical units in Mexico City.

	All patients[a]		Ambulatory[b]		Hospitalized[c]		Non-Critical[d]		Critical[e]	
	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)	P
Models for type of treatment										
No antiviral / antibiotic	Reference		Reference		Reference		Reference		Reference	
Antiviral only	1.72 (1.61-1.84)	<.001	4.7 (3.94-5.62)	<.001	1.07 (0.99-1.15)	.07	2.03 (1.86-2.21)	<.001	1.09 (0.99-1.21)	.09
Antibiotic only	1.13 (1.08-1.19)	<.001	0.72 (0.58-0.89)	.003	0.81 (0.77-0.86)	<.001	1.05 (0.98-1.14)	.2	0.67 (0.63-0.72)	<.001
Antiviral + antibiotic	1.57 (1.47-1.67)	<.001	1.91 (1.47-2.49)	<.001	0.91 (0.86-0.97)	.004	1.63 (1.49-1.77)	<.0001	1.02 (0.93-1.11)	.7
Models for type of antiviral										
No antiviral / antibiotic	Reference		Reference		Reference		Reference		Reference	
Acyclovir	1.37 (0.51-3.65)	.5	Not estimable		2.75 (1.03-7.33)	.04	1.19 (0.29-4.75)	.8	2.85 (0.71-11.4)	.1
Amantadine	0.73 0.44-1.21)	.2	0.08 0.24-2.36)	.6	0.88 (0.5-1.55)	.7	0.67 (0.33-1.34)	.3	1.05 (0.49-2.21)	.9
Lopinavir-Ritonavir	1.04 (0.69-1.55)	.9	4.28 (0.59-30.7)	.1	0.59 (0.4-0.89)	.01	0.69 (0.33-1.46)	.3	0.66 (0.41-1.04)	.08
Oseltamivir	1.66 (1.58-1.75)	<.001	3.52 (3.01-4.11)	<.001	0.98 (0.93-1.03)	.4	1.84 (1.72-1.96)	<.001	1.06 (0.99-1.14)	.1
Rimantadine	1.39 (0.66-2.92)	.4	2.54 (0.36-18.1)	.4	1.11 (0.49-2.46)	.8	1.48 (0.56-3.95)	.4	1.63 (0.52-5.09)	.4
Zanamivir	1.66 (0.83-3.32)	.2	2.49 (0.35-17.8)	.4	0.84 (0.39-1.76)	.6	1.43 (0.46-4.43)	.5	0.7 (0.29-1.69)	.4
Antibiotic only	1.14 (1.08-1.19)	<.001	0.72 (0.58-0.9)	.004	0.81 (0.77-0.86)	<.001	1.06 (0.98-1.14)	.2	0.68 (0.63-0.72)	<.001
Models for Acyclovir										
No antiviral / antibiotic	Reference		Reference		Reference		Reference		Reference	
Acyclovir only	8.1 (1.14-57.6)	.04	Not estimable		8.98 (1.26-63.9)	.03	Not estimable		2.85 (0.39-20.3)	.3
Antibiotic only	1.11 (1.05-1.17)	<.001	0.71 (0.57-0.89)	.002	0.82 (0.77-0.86)	<.001	1.03 (0.96-1.11)	.4	0.67 (0.63-0.72)	<.001
Acyclovir + antibiotic	1.07 (0.35-3.33)	.9	Not estimable		2.28 (0.74-7.08)	.2	1.23 (0.31-4.92)	.8	3.11 (0.44-22.2)	.3
Models for Amantadine										
No antiviral / antibiotic	Reference		Reference		Reference		Reference		Reference	
Amantadine only	1.78 (1.03-3.06)	.04	1.69 (0.42-6.79)	.5	1.62 (0.89-2.93)	.1	1.63 (0.78-3.42)	.2	1.39 (0.62-3.1)	.4
Antibiotic only	1.11 (1.05-1.17)	<.001	0.71 (0.57-0.89)	.002	0.82 (0.77-0.86)	<.001	1.03 (0.96-1.12)	.4	0.67 (0.63-0.72)	<0.001
Amantadine + antibiotic	0.15 (0.04-0.59)	.007	0.34 (0.05-2.39)	.3	0.15 (0.02-1.06)	.06	0.13 (0.02-0.9)	.04	0.44 (0.06-3.11)	.4
Models for Lopinavir-Ritonavir										

	HR (95%CI)[a]	p	HR (95%CI)[b]	p	HR (95%CI)[c]	p	HR (95%CI)[d]	p	HR (95%CI)[e]	p
No antiviral / antibiotic	Reference		Reference		Reference		Reference		Reference	
Lopinavir-Ritonavir only	0.68 (0.26-1.82)	.4	56.9 (7.87-412)	<.001	0.39 (0.15-1.05)	.06	0.47 (0.07-3.37)	.5	0.41 (0.15-1.08)	.07
Antibiotic only	1.11 (1.05-1.17)	<.001	0.71 (0.57-0.89)	.002	0.82 (0.77-0.86)	<.001	1.04 (0.96-1.12)	.4	0.67 (0.63-0.72)	<.001
Lopinavir-Ritonavir + antibiotic	1.1 (0.71-1.7)	.7	Not estimable		0.67 (0.43-1.05)	.08	0.69 (0.31-1.53)	.4	0.79 (0.47-1.34)	.4
Models for Oseltamivir										
No antiviral / antibiotic	Reference		Reference		Reference		Reference		Reference	
Oseltamivir only	1.72 (1.61-1.84)	<.001	4.79 (4.01-5.75)	<.001	1.07 (0.99-1.15)	.06	2.05 (1.88-2.23)	<.001	1.11 (1.0-1.23)	.05
Antibiotic only	1.13 (1.08-1.19)	<.001	0.72 (0.58-0.89)	.003	0.81 (0.77-0.86)	<.001	1.06 (0.98-1.14)	.2	0.67 (0.63-0.72)	<.001
Oseltamivir + antibiotic	1.61 (1.51-1.71)	<.001	2.1 (1.65-2.8)	<.001	0.92 (0.87-0.98)	.01	1.68 (1.55-1.83)	<.001	1.02 (0.94-1.12)	.6
Models for Rimantadine										
No antiviral / antibiotic	Reference		Reference		Reference		Reference		Reference	
Rimantadine only	1.88 (0.85-4.21)	.1	4.9 (0.69-34.9)	.1	1.21 (0.5-2.91)	.7	1.81 (0.58-5.62)	.3	1.69 (0.54-5.27)	.4
Antibiotic only	1.11 (1.05-1.17)	<.001	0.71 (0.57-0.89)	<.001	0.82 (0.77-0.86)	<.001	1.03 (0.96-1.12)	.4	0.67 (0.63-0.72)	<.001
Rimantadine + antibiotic	0.51 0.07-3.6)	.5	Not estimable		0.77 (0.11-5.45)	.8	0.88 (0.12-6.23)	.9	-	-
Models for Zanamivir										
No antiviral / antibiotic	Reference		Reference		Reference		Reference		Reference	
Zanamivir only	1.9 (0.85-4.25)	.12	3.99 (0.55-28.9)	.2	0.9 (0.37-2.17)	.8	1.2 (0.17-8.49)	.9	0.72 (0.29-1.74)	.7
Antibiotic only	1.11 (1.05-1.17)	<.001	0.71 (0.57-0.89)	<.001	0.82 (0.77-0.86)	<.001	1.03 (0.96-1.12)	.4	0.67 (0.63-0.72)	<.001
Zanamivir + antibiotic	1.14 (0.28-4.55)	.9	Not estimable		0.74 (0.18-2.94)	0.7	1.57 (0.39-6.29)	.5	-	-

HR: Hazard ratio, 95%CI: 95% confidence intervals

a: Model adjusted by : Sex (men), Age, Indigenous self-identification, Diabetes, Chronic obstructive pulmonary disease, Immunosuppression, Hypertension, Human immunodeficiency virus/acquired immune deficiency syndrome, Cardiovascular disease, Obesity, Chronic kidney disease, Unemployed, Time from symptom onset to medical attention, Fever, Cough, Shortness of breath, Irritability, Chest pain, Chills, Myalgias, Arthralgias, Abrupt deterioration, Polypnea, Abdominal pain, Cyanosis.

b: Model adjusted by: Sex (men), Age, Indigenous self-identification, Diabetes, Chronic obstructive pulmonary disease, Immunosuppression, Hypertension, Cardiovascular disease, Obesity, Chronic kidney disease, Unemployed, Time from symptom onset to medical attention, Fever, Cough, Shortness of breath, Irritability, Chest pain, Chills, Myalgias, Arthralgias, Abrupt deterioration, Polypnea, Vomit, Abdominal pain, Cyanosis.

c: Model adjusted by: Sex (men), Age, Diabetes, Chronic obstructive pulmonary disease, Immunosuppression, Hypertension, Cardiovascular disease, Chronic kidney disease, Smoker, Unemployed, Cough, Shortness of breath, Chest pain, Chills, Myalgias, Arthralgias, Abrupt deterioration, Polypnea, Cyanosis.

d: Model adjusted by: Sex (men), Age, Indigenous self-identification, Diabetes, Chronic obstructive pulmonary disease, Immunosuppression, Hypertension, Hypertension, Human immunodeficiency virus/acquired immune deficiency syndrome, Cardiovascular disease, Obesity, Chronic kidney disease, Unemployed, Time from symptom onset to medical attention, Fever, Cough, Shortness of breath, Irritability, Chest pain, Myalgias, Arthralgias, Polypnea, Vomit, Abdominal pain, Cyanosis.

e: Model adjusted by: Sex (men), Age, Diabetes, Chronic obstructive pulmonary disease, Immunosuppression, Hypertension, Cardiovascular disease, Chronic kidney disease, Unemployed, Time from symptom onset to medical attention, Cough, Sore throat, Shortness of breath, Chest pain, Headache, Myalgias, Arthralgias, Rhinorrhea, Polypnea, Abdominal pain, Cyanosis.

Figure 1. Flow diagram of patients assessed for eligibility.

Figure 2. Survival of patients (general population, ambulatory, and hospitalized) treated with antivirals and/or antibiotics.

Survival curves are shown according to treatment modality in the general population (a), ambulatory (b), and hospitalized (c) patients. Survival in patients receiving specific antivirals, antibiotics, both, or none in the general population (d), ambulatory (e), and hospitalization (f) settings.

Figure 3. Survival of patients (non-critical and critical) treated with antivirals and/or antibiotics.

Survival curves are shown according to treatment modality in non-critical (a) and critical (b) patients. Survival in patients receiving specific antivirals, antibiotics, both, or none in critical (c) and non-critical (d) patient

Patients evaluated for COVID-19 between February 24 and September 14, 2020		
n = 395,343		

Patients without a positive RT-PCR for SARS-CoV-2
n = 258,331

- Negative   n = 216,262
- Unreleased results/problem with sample   n = 41,564
- Other respiratory viruses   n = 505

Positive RT-PCR for SARS-CoV-2
n = 137,012

Patients who received an unidentified antiviral
n = 137

Fully identified antivirals (if any)
n = 136,875

Groups of antivirals with less than 30 patients
n = 20
- Ribavirin   n = 17
- Valacyclovir   n = 2
- Remdesivir   n = 1

Included for analysis
n = 136,855
- Antiviral only   n = 4,044
- Antibiotic only   n = 13,743
- Antiviral + antibiotic   n = 4,925
- No antiviral/antibiotic   n = 114,143

Antivirals studied
  – Oseltamivir   n = 8,414
  – Amantadine   n = 319
  – Lopinavir-Ritonavir   n = 100
  – Rimantadine   n = 61
  – Zanamivir   n = 39
  – Acyclovir   n = 36